50299-95-1Relevant articles and documents
Synthesis and radioligand binding studies of bis-isoquinolinium derivatives as small conductance Ca2+-activated K+ channel blockers
Graulich, Amaury,Dilly, Sébastien,Farce, Amaury,Scuvée-Moreau, Jacqueline,Waroux, Olivier,Lamy, Cédric,Chavatte, Philippe,Seutin, Vincent,Liégeois, Jean-Fran?ois
, p. 5070 - 5075 (2007)
Starting from the scaffold of N-methyllaudanosine and N-methylnoscapine, which are known small conductance Ca2+-activated K+ channel blockers, original bis-isoquinolinium derivatives were synthezised and evaluated using binding studies, electrophysiology, and molecular modeling. These quaternary compounds are powerful blockers, and the most active ones have 10 times more affinity for the channels than dequalinium. The unsubstituted compounds possess a weaker affinity than the analogues having a 6,7-dimethoxy- or a 6,7,8-trimethoxy substitution. The length of the linker has no influence in the alkane derivatives. In relation to the xylene derivatives, the affinities are higher for the ortho and meta isomers. These results are well corroborated by a molecular modeling study. Finally, the most effective compounds have been tested in electrophysiological experiments on midbrain dopaminergic neurons and demonstrate the blocking potential of the apamin-sensitive after- hyperpolarization.
Bis-tetrahydroisoquinoline derivatives: AG525E1, a new step in the search for non-quaternary non-peptidic small conductance Ca2+-activated K+ channel blockers
Graulich, Amaury,Lamy, Cédric,Alleva, Livia,Dilly, Sébastien,Chavatte, Philippe,Wouters, Johan,Seutin, Vincent,Liégeois, Jean-Fran?ois
experimental part, p. 3440 - 3445 (2009/04/06)
So far, small conductance Ca2+-activated K+ channel (SK) blockers mostly consist of quaternary ammonium derivatives or peptides. Due to their physicochemical properties, these blockers are not suitable to study the physiological role
FUNGAL CELL WALL SYNTHESIS GENE
-
, (2008/06/13)
A reporter system reflecting the transport process that transports GPI-anchored proteins to the cell wall was constructed and compounds inhibiting this process were discovered. Further, genes conferring resistance to the above compounds were identified and methods of screening for compounds that inhibit the activity of the proteins encoded by these genes were developed.Therefore, through the novel compounds, the present invention showed that antifungal agents having a novel mechanism, i.e. inhibiting the process that transports GPI-anchored proteins to the cell wall, could be achieved.